

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-9. (Cancelled).

10. (Currently Amended) A method for the treatment or disorders caused by andropause by administering to a subject diagnosed with andropause and having a disorder selected from the group consisting of reduced libido or sexual drive and reduced quality of erections, depression of mood[[,]] and fatigue, an effective amount of propionyl L-carnitine in combination with acetyl L-carnitine or one of their pharmaceutically acceptable salts the improvement comprising a lack of increase of blood testosterone levels.

11. (Currently Amended) The method according to claim 10, in which the andropause is caused by aging ageing.

12. (Previously Presented) The method according to claim 10, in which the andropause is caused by chemical or surgical castration.

13. (Cancelled).

14. (Previously Presented) The method according to claim 10, in which the pharmaceutically acceptable salt is selected from the group consisting of: chloride, bromide, orotate, acid aspartate, acid citrate, magnesium citrate, acid phosphate, fumarate and acid fumarate, magnesium fumarate, lactate, maleate and acid maleate, mucate, acid oxalate, pamoate, acid pamoate, acid sulphate, glucose phosphate, tartrate, acid tartrate, magnesium tartrate, 2-aminoethane sulphonate, magnesium 2-aminoethane sulphonate, choline tartrate and trichloroacetate.

15. (Previously Presented) The method according to claim 10, in which propionyl

L-carnitine in combination with acetyl L-carnitine are in a unit dosage form containing from 4.0g to 0.50 g of propionyl L-carnitine inner salt, and from 0.50 g to 4.0 g of acetyl L-carnitine inner salt or an equimolar amount of one of their pharmaceutically acceptable salts.

16. (Previously Presented) The method according to claim 15, in unit dose form containing 2 g of propionyl L-carnitine inner salt and 2 g of acetyl L-carnitine inner salt, or an equimolar amount of one of their pharmaceutically acceptable salts.

17. (Previously Presented) The method according to claim 15, in which propionyl L-carnitine in combination with acetyl L-carnitine are formulated together, as a mixture, or are formulated separately.

18. (Previously Presented) The method according to claim 17, in which propionyl L-carnitine in combination with acetyl L-carnitine are in a form suitable for oral or parenteral administration.